Global Biosensors Market Overview

The global biosensors market size was valued at USD 30.0 billion in 2024 and is projected to reach USD 48.6 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market growth is primarily driven by the expanding range of medical applications, the increasing prevalence of diabetes, growing demand for compact diagnostic devices, and rapid technological advancements.

Accurate and early disease diagnosis plays a crucial role in improving patient outcomes and survival rates. In recent years, there has been a sharp rise in the demand for disposable, affordable, and rapid-response diagnostic devices. The COVID-19 pandemic further accelerated the biosensors industry, as early detection technologies became essential for disease monitoring and control.

The market is poised for substantial expansion, supported by continuous technological progress and strategic initiatives by major players. For example, in January 2023, Intricon established a Biosensors Center of Excellence (CoE) to strengthen its vertically integrated biosensor development capabilities for medical applications — underscoring the company’s commitment to innovation-driven growth.

Order a free sample PDF of the Biosensors Market Intelligence Study, published by Grand View Research.

Emerging Trends and Innovations

Nanotechnology-based biosensors are anticipated to see broad applications across industries such as food safety testing, imaging, and microbial activity monitoring. The market is undergoing consolidation, driven by increasing adoption of non-invasive biosensors, the rising popularity of medical devices and specialty drugs, and growing research collaborations among manufacturers.

For instance, Ethicon Endo-Surgery Inc., under contracts facilitated by Johnson & Johnson Innovation, has contributed to industry expansion through collaborative research and development. Another notable factor fueling market growth is the rising awareness of continuous health monitoring, particularly among athletes, who increasingly use Electromyography (EMG) biosensors for real-time health tracking and performance optimization.

In December 2022, Nix Biosensors launched its first consumer product, the Nix Hydration Biosensor, featuring a Bluetooth-enabled reusable module, a mobile app, and a single-use patch—illustrating the trend toward personalized, data-driven wellness technologies.

However, the market faces challenges such as stringent regulatory frameworks, complex reimbursement policies, and slow regulatory adaptation to new technologies, which can impede product adoption. Nonetheless, ongoing government programs supporting proteomics and genomics research are expected to create new opportunities for market development.

Key Market Trends & Insights

• North America held the largest revenue share of over 40.2% in 2024.
• Asia Pacific is projected to record the fastest CAGR of 9.9% from 2025 to 2030.
• By technology, the electrochemical segment accounted for around 71.7% of the market share in 2024.
• Based on application, the medical segment dominated with approximately 66.8% of total revenue in 2024.
• In terms of end users, point-of-care testing biosensors led the market, holding a 47.9% revenue share in 2024.

Market Size & Forecast

• 2024 Market Size: USD 30.0 billion
• 2030 Projected Market Size: USD 48.6 billion
• CAGR (2025–2030): 8.6%
• North America: Largest market (2024)
• Asia Pacific: Fastest growing region

Competitive Landscape

The biosensors market is highly competitive, with key players adopting strategies such as product innovation, mergers & acquisitions, collaborations, and geographic expansion to strengthen their market presence.

Major Companies Include:

• Abbott Laboratories
• Medtronic
• Biosensors International Group, Ltd.
• Pinnacle Technology, Inc.
• DuPont
• Sensirion AG
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche AG
• Siemens Healthineers
• Zimmer & Peacock AS
• Metrohm AG
• DexCom, Inc.
• Universal Biosensors, Inc.
• Johnson & Johnson Services, Inc.
• Nix Biosensors
• Cyrcadia Health
• Lifescan

Company Highlights:

• Medtronic operates globally in over 160 countries, offering device-based medical therapies across four major segments: minimally invasive therapies, cardiac & vascular, restorative, and diabetes care. The company markets its solutions through both direct and independent distribution channels worldwide.
• Abbott Laboratories functions across four key segments—pharmaceuticals, diagnostics, nutrition, and medical devices—and is a leader in blood glucose monitoring systems. Through its subsidiary St. Jude Medical, Abbott continues to expand its global healthcare impact.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion

The global biosensors market is entering a phase of sustained growth, driven by technological innovation, increasing healthcare awareness, and expanding applications beyond medical diagnostics. While regulatory and reimbursement challenges may constrain rapid adoption, ongoing government initiatives in genomics and proteomics, along with strategic advancements by industry leaders, are expected to propel the market forward.

With strong demand across North America and accelerating growth in Asia Pacific, the biosensors market is poised to achieve USD 48.6 billion by 2030, marking a significant transformation toward more efficient, accessible, and personalized healthcare solutions.